Fezolinetant Dosage
Medically reviewed by Drugs.com. Last updated on Sep 13, 2023.
Applies to the following strengths: 45 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Postmenopausal Symptoms
Recommended dose: 45 mg orally once a day
Comments:
- Evaluate liver function prior to treatment initiation and as recommended.
- The benefit and duration of treatment should be periodically assessed based on the history and course of the vasomotor symptoms (VMS); no data available beyond 12 months.
Use: For the treatment of moderate to severe VMS associated with menopause
Renal Dose Adjustments
Mild or moderate renal dysfunction (estimated GFR greater than 30 mL/min/1.73 m2): No dose adjustment recommended
Severe renal dysfunction or end-stage renal disease (estimated GFR less than 30 mL/min/1.73 m2): Contraindicated
Liver Dose Adjustments
Mild liver dysfunction (Child-Pugh A): No adjustment recommended
Moderate or severe liver dysfunction (Child-Pugh B or C): Contraindicated
Precautions
The following product is subject to additional monitoring: Veoza
CONTRAINDICATIONS:
- Known hypersensitivity to either the active component or to any of the ingredients
- Concomitant use of moderate or strong CYP450 1A2 inhibitors
- Pre-existing Child-Pugh B or C chronic hepatic impairment
- Severe or end stage renal impairment (estimated GFR less than 30 mL/min/1.73 m2)
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- For oral use
- Before starting treatment, perform baseline liver function tests.
- Administer with or without food at about the same time each day.
- This drug should be given with liquid and swallowed whole; do not crush, cut, or chew tablets.
- Missed doses should be taken as soon as possible, unless the next scheduled dose is within 12 hours.
Storage requirements: Store below 30C.
Monitoring:
- Drug interactions: For potential use of CYP450 1A2 inhibitors (prior to and during therapy)
- General: For treatment benefit (periodically during therapy)
- Hepatic: Liver function tests (at baseline and at least once within first 3 months of therapy)
Patient advice:
- Read the Consumer Medicine Information.
- Understand that blood tests to evaluate liver function are required prior to therapy and then periodically.
- Report all medication and supplement use to your health care provider.
- Patients of childbearing potential: Notify a health care provider of a known or suspected pregnancy, or if breastfeeding.
More about fezolinetant
- Check interactions
- Compare alternatives
- Reviews (54)
- Latest FDA alerts (2)
- Side effects
- During pregnancy
- Drug class: miscellaneous central nervous system agents
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.